Arcus Biosciences, Inc. (RCUS)
29.71
+0.43
(+1.47%)
USD |
NYSE |
Sep 01, 16:00
29.72
+0.01
(+0.03%)
After-Hours: 20:00
Arcus Biosciences Cash from Investing (Quarterly) : 52.00M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 52.00M |
| March 31, 2026 | 114.00M |
| December 31, 2025 | -182.00M |
| September 30, 2025 | 79.00M |
| June 30, 2025 | 137.00M |
| March 31, 2025 | 32.00M |
| December 31, 2024 | 51.00M |
| September 30, 2024 | -29.00M |
| June 30, 2024 | 63.00M |
| March 31, 2024 | -169.00M |
| December 31, 2023 | 28.00M |
| September 30, 2023 | 11.00M |
| June 30, 2023 | 26.00M |
| March 31, 2023 | 129.00M |
| December 31, 2022 | 46.81M |
| September 30, 2022 | 23.45M |
| June 30, 2022 | -215.20M |
| March 31, 2022 | -268.06M |
| Date | Value |
|---|---|
| December 31, 2021 | 18.91M |
| September 30, 2021 | -88.61M |
| June 30, 2021 | 3.003M |
| March 31, 2021 | 62.83M |
| December 31, 2020 | -0.231M |
| September 30, 2020 | -387.12M |
| June 30, 2020 | -87.07M |
| March 31, 2020 | 40.06M |
| December 31, 2019 | -12.10M |
| September 30, 2019 | 30.36M |
| June 30, 2019 | 26.67M |
| March 31, 2019 | 14.28M |
| December 31, 2018 | 2.511M |
| September 30, 2018 | -83.34M |
| June 30, 2018 | -16.12M |
| March 31, 2018 | -16.49M |
| December 31, 2017 | -49.07M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | -62.66M |
| AVITA Medical, Inc. | 3.947M |
| Iovance Biotherapeutics, Inc. | -74.05M |
| Editas Medicine, Inc. | -29.80M |
| Recursion Pharmaceuticals, Inc. | -1.959M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -119.00M |
| Cash from Financing (Quarterly) | 16.00M |
| Free Cash Flow | -475.00M |
| Free Cash Flow Per Share (Quarterly) | -0.9437 |
| Free Cash Flow to Equity (Quarterly) | -120.00M |
| Free Cash Flow to Firm (Quarterly) | -116.00M |
| Free Cash Flow Yield | -13.42% |